Interference with SPARC inhibits Benzophenone-3 induced ferroptosis in osteoarthritis: Evidence from bioinformatics analyses and biological experimentation

• Published in: Ecotoxicology and environmental safety Vol. 274; p. 116217
• Main Authors: Nie, Yaoyao, Liu, Houpu, Wu, Runtao, Fan, Jiayao, Yang, Ye, Zhao, Wenxia, Bao, Jiapeng, You, Zhenqiang, He, Fan, Li, Yingjun
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.04.2024; Elsevier
• Subjects: Benzophenone-3; Ferroptosis; Osteoarthritis; SPARC; SPARC; DMSO; SPE; Ferroptosis; MDA; SiRNA; BSA; OA; KEGG; GSH; PBS; UV; OR; Benzophenone-3; CI; GO; DAPI; BP-3; PVDF; OMM; ECM; MMP; CCK8; HPLC-MS/MS; ECHA; NHANES; TEM; Osteoarthritis
• ISSN: 0147-6513; 1090-2414
• DOI: 10.1016/j.ecoenv.2024.116217

The aim of this study is to conduct a thorough evaluation of the association between Benzophenone-3 (BP-3) exposure and OA, offering critical insights into the underlying mechanisms involved. The National Health and Nutrition Examination Survey (NHANES) database was utilized to investigate the correlation between BP-3 and osteoarthritis. Proteomic sequencing from clinical sample and the PharmMapper online tool were employed to predict the biological target of BP-3. Cellular molecular assays and transfection studies were performed to verify the prediction from bioinformatics analyses. Through cross-sectional analysis of the NHANES database, we identified BP-3 as a risk factor for OA development. The results of proteomic sequencing showed that Secreted Protein Acidic and Rich in Cysteine (SPARC) was significantly elevated in the area of damage compared to the undamaged area. SPARC was also among the potential biological targets of BP-3 predicted by the online program. Through in vitro cell experiments, we further determined that the toxicological effects of BP-3 may be due to SPARC, which elevates intracellular GPX4 levels, activates the glutathione system, and promotes lipid peroxidation to mitigate ferroptosis. Inhibiting SPARC expression has been shown to reduce inflammation and ferroptosis in OA contexts. This research provides an expansive understanding of BP-3's influence on osteoarthritis development. We have identified SPARC as a potent target for combating chondrocyte ferroptosis in BP-3-associated osteoarthritis. •BP-3 is demonstrated to be linked to an increased prevalence of OA in a larger population sample.•SPARC is the target protein of BP-3 in human body.•SiSPARC can inhibit ferroptosis and reduce BP-3 induced chondrocyte injury.•SPARC is a potential therapeutic target for OA precipitated by BP-3.•BP-3 activates ferroptosis to induce OA by targeting SPARC.